January 16, 2025

Study Questions Urokinase's Role in Minor Stroke Care

For minor stroke patients, urokinase showed no added benefit for 90-day outcomes but remained safe, TRUST trial reveals.

Conexiant

January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 15, 2025

Waist Circumference Predicts Pediatric Steatotic Liver

This study explores the role of waist circumference, body mass index, and high-sensitivity C-reactive protein in pediatric steatotic liver disease, identifying waist circumference as a significant non-invasive screening tool.

Conexiant

January 15, 2025

CMR-PCWP Correlates with Heart Failure Biomarkers

In HFrEF patients, cardiovascular magnetic resonance-estimated pulmonary capillary wedge pressure "correlates with clinical and ultrasound markers of congestion," demonstrates potential as a non-invasive alternative to traditional pressure measurements.

Conexiant

January 14, 2025

Low-Carb Diet Improves Reflux and GI Health in Obesity Study

Low-carb, high-fat diets reduced reflux symptoms and altered short-chain fatty acids in obesity.

Conexiant

January 14, 2025

Remnant Cholesterol as Biomarker for Endometriosis, Study

‘An increase of one unit in RC was linked to a 135% rise in the likelihood of developing endometriosis,’ positioning remnant cholesterol as a promising marker for risk assessment.

Conexiant

January 13, 2025

Heart Age vs. CVD Risk in Care

Explore how heart age and short-term cardiovascular disease risk differ in guiding preventive care.

Conexiant

January 13, 2025

HF Event Reduction with Ertugliflozin: VERTIS CV

Ertugliflozin significantly reduces heart failure events in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Conexiant